Michael P Graziano

Title: Michael P Graziano: Innovator in Cholesterol Absorption and Thrombin Receptor Antagonism

Introduction

Michael P Graziano is a notable inventor based in Scotch Plains, NJ (US). He holds a total of 8 patents that contribute significantly to the fields of biochemistry and pharmacology. His work primarily focuses on the development of compounds that inhibit cholesterol absorption and act as thrombin receptor antagonists.

Latest Patents

One of his latest patents involves the use of azetidinone compounds. These compounds serve as inhibitors of cholesterol absorption and are valuable tools for discovering and characterizing proteins involved in the trafficking or absorption of cholesterol and cholesteryl esters in biological systems. The invention highlights how these compounds can be utilized in competitive binding assays to identify other chemical agents that may also function as cholesterol absorption inhibitors. Additionally, new compounds developed in this patent are recognized as highly efficacious inhibitors of cholesterol absorption.

Another significant patent by Graziano focuses on constrained himbacine analogs as thrombin receptor antagonists. This patent discloses a compound represented by a specific structural formula, along with pharmaceutical compositions and combinations that include these compounds. Their applications extend to functioning as thrombin receptor antagonists and binders to cannabinoid receptors.

Career Highlights

Throughout his career, Michael P Graziano has worked with prominent companies such as Schering Corporation and Merck & Co., Inc. His contributions to these organizations have been instrumental in advancing research and development in the pharmaceutical industry.

Collaborations

Graziano has collaborated with notable colleagues, including Scott W Altmann and Duane A Burnett. These partnerships have fostered innovation and have led to significant advancements in their respective fields.

Conclusion

Michael P Graziano's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents not only advance scientific understanding but also pave the way for new therapeutic options in cholesterol management and receptor antagonism.